Limited by the expression profile of FcγRIIB mainly on B cells, macrophages and DCs accumulated in the tumor microenvironment, FcγRIIB-dependent TNFRSF antibodies are predicted to have a narrower scope of co-stimulating targeted cells and less systemic side effects. Here, FCGR2B is linked to neoplasm.